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1ABSTRACT
Positive-strand RNA viruses are divided 
into large groups termed superfamilies, the 
members of which share common features 
in their encoded replicase proteins, genome 
organization and replication strategies. The 
purpose of this work was to characterize 
the properties of hepatitis E virus (HEV) 
and Semliki Forest virus (SFV) replicase 
proteins. These distantly related viruses 
belong to the alphavirus-like superfamily 
of positive-strand RNA viruses.
In the fi rst part of this study, an N-
terminal fragment of hepatitis E virus 
replicase was shown to possess both 
methyltransferase and guanylyltransferase 
activities, required for capping of viral 
mRNA. Hepatitis E virus capping enzyme 
utilizes a unique mechanism of cap 
formation. The capping enzyme of HEV 
fi rst acts as a methyltransferase, catalyzing 
the transfer of a methyl group from S-
adenosylmethionine to GTP to yield 7-
methyl-GTP. The capping enzyme then 
acts as a guanylyltransferase, transferring 
the methylated guanosine to mRNA via 
a covalent complex. This virus-specifi c 
pathway is conserved within members of 
the alphavirus-like superfamily. Therefore, 
these capping reactions offer attractive 
targets for the development of antiviral 
drugs.
The second part of this work deals 
with the Semliki Forest virus replication 
complex. We studied the role of Semliki 
Forest virus nonstructural polyprotein 
in the formation and targeting of the 
replication complex by expressing its 
cleavable and uncleavable intermediates. 
The uncleaved polyproteins possessed 
properties previously identifi ed for the 
individual nonstructural proteins. We 
demonstrated that only polyprotein-
derived nonstructural proteins were able to 
assemble into a complex. The study verifi ed 
that nonstructural protein nsP1 alone was 
responsible for the membrane association 
of the nonstructural polyprotein.
The same methods were used to study 
expression and membrane association 
of the HEV large nonstructural protein 
encoded by ORF1 of the genome RNA. 
We expressed the full-length pORF1 and 
its shorter fragments in mammalian cells. 
By subcellular fractionation experiments 
and immunofl uorescence microscopy we 
observed that HEV replicase is tightly 
associated with the membranes and is 
localized in the perinuclear region of the 
cell. Results indicated that the localization 
signal, which directs HEV polyprotein to 
a specifi c membrane region in the cell, is 
located in its N-terminal part.
In the last part of the thesis we describe 
already existing antiviral compounds 
and propose novel potential targets. All 
steps in the virus life cycle are, in theory, 
equally appropriate for the development 
of antiviral drugs. Major research efforts 
have been focused on the enzymes that 
mediate viral replication. Among them, 
proteases and polymerases have been the 
most popular targets of antiviral research 
during the past years. The present work 
describes the capping enzyme of alpha-
like viruses that is a novel target for the 
development of specifi c inhibitors against 
viral replication.
Abstract
2INTRODUCTION
1. ALPHAVIRUS-LIKE 
SUPERFAMILY
Viruses with single-strand positive-sense 
RNA genomes represent the largest class 
of viruses. This diverse group of viruses 
includes major pathogens of vertebrate 
and invertebrate animals, plants, fungi 
and bacteria. The high mutation rate is 
typical for RNA viruses and must have 
played an important role in the evolution 
of viral populations and their adaptation 
to environmental changes (Domingo et al, 
1999). Progress in sequencing techniques 
and computer-assisted comparative 
studies has led to an understanding of 
the relationships within this class of 
viruses. Positive-strand RNA viruses can 
be categorized into large groups termed 
superfamilies, the members of which 
share common features in their encoded 
replicase proteins, genome organization 
and replication strategies (reviewed in 
Koonin and Dolja, 1993). Such conserved 
proteins include RNA-dependent RNA 
polymerase (POL), RNA helicase (HEL), 
chymotrypsin-like and papain-like 
proteases (PRO) and methyltransferases 
(MT). A comparative analysis of amino acid 
sequences of viral proteins suggests that 
there are three superfamilies of positive-
sense RNA viruses, i.e., the picornavirus-
like, alphavirus-like and fl avivirus-like 
(reviewed in van der Heijden and Bol, 
2002).
Amongst the members of the 
alphavirus-like superfamily are animal 
viruses from the family Togaviridae 
(genera Alphavirus and Rubivirus) and 
Hepeviridae (Hepatitis E virus), insect 
viruses of the Tetraviridae family, as well as 
numerous groups of plant viruses, including 
Bromoviridae, Closteroviridae, and the 
genera Tobamo-, Tobra-, Hordei-, Furo-, Beny-, 
Capillo-, Tymo-, Carla- and Potexvirus, and 
other plant virus groups. Members of this 
group of viruses feature many similarities. 
The three conserved domains are always 
organized in the same order MT-HEL-
POL (reviewed in Kääriäinen and Ahola, 
2002; van der Heijden and Bol, 2002). 
The methyltransferase (or recently termed 
capping enzyme) is the hallmark of the 
alphavirus-like superfamily, as it is present 
in all members of the family (Rozanov et 
al., 1992) (Fig.1). In addition, members 
of the alphavirus-like superfamily share 
capped 5′ end of positive-strand mRNAs, 
membrane-associated replication complex, 
an extra untemplated G residue at the 3′ 
end of minus strand, asymmetric RNA 
synthesis with an excess of plus-strand 
RNA, and transcription of one or more 
subgenomic RNAs. Many viruses utilize 
translational readthrough of a termination 
codon to synthesize the RNA polymerase 
(reviewed in Strauss and Strauss, 1994). 
There are also many differences among 
the viruses that might have appeared at 
later stages of evolution. For example, 
the genome can consist of a single RNA 
or be segmented. In alphaviruses, the 
nonstructural proteins are proteolytically 
processed by virus-encoded papain-like 
protease, but this function is not present in 
most of the plant viruses. On the other hand, 
plant viruses possess genes for movement 
within the plant that are not present in 
the alphavirus genome. The structural 
proteins are of different origin, which 
leads to viruses with various structures 
(Strauss and Strauss, 1994, Kääriäinen 
and Ahola, 2002). The degree of sequence 
conservation between homologous viral 
proteins is relatively low. As a rule, 
among distant groups of viruses, only 
short amino acid sequence motifs that are 
directly involved in enzymatic function 
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3are conserved (reviewed in Koonin and 
Dolja, 1993). Nevertheless, the conserved 
order of capping enzyme, helicase and 
polymerase domains suggests that the 
composition of the replication complexes 
is similar among the members of the 
alphavirus-like superfamily.
1. 1. Plant alpha-like viruses
Plant viruses from the alphavirus-like 
superfamily use several different strategies 
to express their replicase proteins. For 
example, Bamboo mosaic virus (BaMV), 
a member of genus Potexvirus, expresses 
a single 155-kDa polypeptide that has all 
three domains methyltransferase, helicase 
and polymerase. Other viruses regulate the 
production of different amount of partial 
and complete replicase proteins by (i) 
ribosomal readthrough or frameshifting, 
(ii) expression from two different RNAs, 
or (iii) proteolytic modifi cation (reviewed 
in van der Heijden and Bol, 2002). 
Tobacco mosaic virus (TMV), type 
member of the genus Tobamovirus 
expresses a polyprotein (183 kDa) 
containing all three domains MT, HEL 
and POL in the same sequence after the 
readthrough of an amber stop codon before 
the POL domain. The major translation 
product is smaller (126 kDa) and contains 
only the MT and HEL domains. The 
tobamoviruses share this strategy with 
viruses from the genera Tobravirus, 
Furovirus, Pomovirus and Pecluvirus (van 
der Heijden and Bol, 2002). 
MT HEL POLXPRO?
MT
MT
MT
MT
MT
MT
X
X HEL
HEL
HEL
HEL
HEL
HEL
POL
POL
MT HEL POL
POL
POL
POL
POL
PRO
PRO
MT HEL POL
PRO
PRO
ANIMAL VIRUSES
hepevirus
INSECT VIRUSES
betatetra/omegatetraviruses
PLANT VIRUSES
potex, idaeo, allexi, foreaviruses
tobamo, tobra, furo, pomo, pecluviruses
alphavirus
rubivirus
bromo, cucumo, alfamo, 
ilar, olea, hordeiviruses
tymo, carlaviruses
benyviruses
Figure 1. Schematic representation of the genome organization of alpha-like viruses (modifi ed 
from van der Heijden and Bol, 2002). Methyltransferase (MT), helicase (HEL) and polymerase 
(POL) domains are present in all members of the family. An additional X domain is present 
in animal viruses. Some viruses encode the POL domain via the read-through of a leaky stop 
codon (▼).
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4Brome mosaic virus (BMV), type 
member of the genus Bromovirus, 
expresses two replicase proteins. Protein 
1a is similar to TMV p126 and contains 
capping enzyme and helicase domains. 
BMV protein 2a contains only the POL 
domain (Ahola and Ahlquist, 1999). This 
strategy for expression of replicase proteins 
from two different RNAs is also used by 
other members of the Bromoviridae family 
and by the hordeiviruses.
Like alphaviruses, tobacco mosaic 
virus (Merits at al., 1999), brome mosaic 
virus (Ahola and Ahlquist, 1999) and 
bamboo mosaic virus (Li et al., 2001) 
synthesize cap for their mRNAs in 
different manner than their host cells. The 
cap formation pathway is described in 
detail later in this study.
1. 2. Animal alpha-like viruses
Animal infecting viruses from the 
alphavirus-like superfamily include viruses 
from genera Alphavirus and Rubivirus of 
the Togaviridae family and hepatitis E virus 
of the Hepeviridae family (Koonin at al., 
1992). All animal viruses from the alpha-
like supergroup encode their proteins in a 
single genomic RNA. Characteristic for 
animal alpha-like viruses is the presence 
of a conserved domain, known as the X 
domain, the function of which remains to 
be determined. The X domain is associated 
with papain-like proteases in alphaviruses 
and Rubella virus (RUB) and is preceded 
by a proline-rich region in RUB and HEV. 
Another conserved domain with unknown 
function, so-called Y domain, resides 
downstream of the methyltransferase 
domain in rubella and hepatitis E virus, 
but is not found in alphaviruses (Koonin at 
al., 1992, Koonin and Dolja, 1993).
2. ALPHAVIRUSES
Alphaviruses are enveloped positive-strand 
RNA viruses that are widely distributed 
throughout the world. They are transmitted 
to vertebrate hosts by mosquitos. The 
alphavirus genus consists of about 30 
members, some of which are pathogenic 
to humans or domestic animals, causing 
serious central nervous system infections 
or milder infections with symptoms like 
fever, rash and arthritis (Strauss and 
Strauss, 1994).
The best characterized alphaviruses, 
Sindbis virus (SIN) and Semliki Forest 
virus, have been extensively studied 
for the last 30 years. Alphaviruses 
have been used as molecular probes to 
study the modifi cation and transport of 
glycoproteins, as well as endocytosis and 
membrane fusion events (Helenius, 1995, 
Ellgaard and Helenius, 2003). Alphaviruses 
have been successfully used as expression 
vectors, due to their broad host range and 
effi cient cytoplasmic gene expression 
in a variety of cell types (Liljeström and 
Garoff, 1991). 
As a result of increased understanding 
of the molecular events during infection, 
alphaviruses together with the well-
studied plant alpha-like viruses, primarily 
Brome mosaic and Tobacco mosaic 
viruses, became one of the most advanced 
model systems to study the replication of 
positive-strand RNA viruses (Kääriäinen 
and Ahola, 2002).
2. 1. Replication cycle
The alphavirus particles are icosahedral 
with a diameter of 700 Ả. The virion 
consists of one copy of RNA (11.5 kb for 
SFV) enclosed in a capsid surrounded 
by an envelope. The virus envelope is 
built by heterodimers of transmembrane 
glycoproteins E1 and E2, which form 
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580 morphologically distinct spikes. In 
SFV a third glycoprotein, a peripherally 
bound E3, is associated with the E1-
E2 dimer. The envelope surrounds the 
nucleocapsid, which is formed by 240 
copies of a capsid protein arranged in 
pentamers and hexamers (Strauss and 
Strauss, 1994).  The attachment of the 
virus particle to the cell surface is mainly 
directed by E2, while E1 is required for 
the membrane fusion between the viral 
envelope and target membrane (Marsh and 
Helenius, 1989, Helenius, 1995). In order 
to infect a variety of hosts, alphaviruses 
must use different receptor molecules for 
attachment. Laminin receptor has been 
identifi ed as a receptor for SIN (Wang et 
al., 1992). Other receptors are very poorly 
characterized. The virus enters the cell 
via receptor-mediated endocytosis, which 
is followed by conformational changes 
in the envelope triggered by low pH. As 
a result, nucleocapsid is released into the 
cytoplasm, where uncoating of the genome 
RNA is mediated by ribosomes (Singh and 
Helenius, 1992).   
The alphavirus RNA replication takes 
place in the cytoplasm of the infected cells 
in association with membranes (Ranki and 
Kääriäinen, 1979). The single-stranded 
positive-sense genome RNA contains 
a 5′ end cap and 3′ end polyA tail and is 
used directly as mRNA (Kääriäinen and 
Söderlund, 1978). The 5′ two-thirds of the 
SFV 42S RNA genome is translated into 
a large polyprotein of 2432 aa, designated 
P1234, which is autocatalytically processed 
to yield nonstructural protein nsP4 and 
P123 (Fig.2). This is the “early RNA 
polymerase” responsible for the synthesis 
of full-size complementary RNA (42S 
RNA minus strand). After further cleavage 
of P123 into nsP1, nsP2 and nsP3, the 
minus strand in turn acts as a template for 
the synthesis of new 42S RNA plus strand, 
as well as subgenomic 26S RNA of the 
structural proteins (Kim et al., 2004).
The translation of 26S RNA leads 
to production of alphavirus structural 
proteins; which are synthesized as a 
C-p62-6K-E1 polyprotein precursor. 
The amino-terminal capsid protein C 
autoproteolytically cleaves itself from 
the nascent chain and interacts with the 
genomic RNA in the cytoplasm to form 
a nucleocapsid. The envelope proteins 
are cotranslationally inserted into the 
endoplasmic reticulum (ER) and are 
transported to the plasma membrane via the 
Golgi complex. During transit, the p62-E1 
heterodimeric complexes are cleaved into 
mature E1 and E2 heterodimers, which are 
then oligomerized into spikes (reviewed 
in Garoff et al., 2004). The formation of 
an envelope around the viral nucleocapsid 
and the release of virus particles from the 
infected cells by budding are driven by 
the interaction of the virus spike proteins 
and the nucleocapsid (Suomalainen et al., 
1992).  
Replication of all positive-strand 
RNA viruses of eukaryotes takes place 
in association with membranes. Different 
viruses utilize various intracellular 
membrane compartments and cause 
diverse modifi cations and rearrangements 
of the target membrane (Salonen et al., 
2005). Viruses of family Togaviridae 
use membranes from endo- and 
lysosomal compartments. Semliki Forest 
virus replicase proteins together with 
synthesized RNA were found in vacuoles 
defi ned as cytopathic vacuoles type I 
(CPV-1) (Grimley et al., 1968; Salonen 
et al., 2005). Rubella virus replicates in 
cytoplasmic structures morphologically 
analogous to the alphavirus CPVs 
(Kujala et al., 1999). Plant viruses of the 
alphavirus-like superfamily replicate on 
various intracellular membranes. For 
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6example, brome mosaic virus and tobacco 
mosaic virus use the ER membrane as the 
site of their replication, alfalfa mosaic 
virus replicates on the vacuolar membrane 
and turnip yellow mosaic virus on the 
chloroplast envelope (Restrepo-Hartwig 
and Ahlquist, 1996; Mas and Beachy, 1999; 
van der Heijden et al., 2001, Prod′homme 
et al., 2001). 
2. 2. Properties of nonstructural proteins
2. 2. 1. NsP4
The size of nsP4 varies between 607-
614 aa in alphaviruses and it is the most 
conserved of replicase proteins. It is 
considered to be the catalytic subunit of 
RNA polymerase. The C-terminal region 
of nsP4 (approximately aa 280-530) 
contains sequence elements typical for 
all RNA-dependent RNA polymerases, 
including the universal GDD motif (Poch 
et al, 1989; Koonin, 1991). Furthermore, 
the large C-terminal part of the protein (aa 
110-610) is related to replicase proteins 
from the alphavirus-like superfamily 
(Koonin and Dolja, 1993). Genetic data 
from temperature sensitive (ts) mutants 
supports the role of nsP4 as the RNA 
polymerase. In SIN ts6 (mutation G153E), 
all viral RNA synthesis stops when cells are 
shifted to the nonpermissive temperature 
at any stage of infection, but synthesis is 
reversible upon shift to the permissive 
temperature (Keränen and Kääriäinen, 
1979; Sawicki et al., 1981). The amount 
of nsP4 in alphavirus infected cells is low 
in comparison to the other nsPs. In most 
alphaviruses nsP4 is only produced as a 
result of the translational read-through 
Figure 2. Translational strategy and proteolytic processing of SFV nonstructural and structural 
proteins
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7of an opal codon (UGA). Additionally, 
nsP4 is rapidly degraded by an N-end rule 
pathway in proteosomes (de Groot at al., 
1991, Takkinen at al., 1991). Presumably 
only the nsP4 fraction, which is assembled 
into replication complex, is stable and 
protected from proteosomal degradation.
2. 2. 2. NsP3
The specifi c biochemical functions of 
nsP3 (SFV 482 aa) are still unknown, 
although genetic studies demonstrated that 
it is essential for the alphavirus replication 
(Hahn et al., 1989). It has been reported 
to affect minus-strand and subgenomic 
RNA synthesis (LaStarza et al., 1994; 
Wang et al., 1994). The N-terminal part of 
nsP3 is conserved among the alphaviruses 
and homologous sequences were found 
in rubella and hepatitis E viruses, and in 
coronaviruses as well (Koonin and Dolja, 
1993). Remarkably, the same domain 
was found also in bacteria, archae and 
eukaryotes (Pehrson and Fuji, 1998, 
Karras et al., 2005). The conservation of 
this domain during evolution suggests 
its importance, however its function 
remains to be determined. In contrast, 
the C-terminal part of nsP3, rich in 
serine, threonine and acidic residues, 
is not conserved in length or sequence 
(Strauss and Strauss, 1994). This region 
is phosphorylated heavily on serines and 
less heavily on threonines (Peränen at al., 
1988, Vihinen and Saarinen, 2000). The 
SFV mutant encoding nonphosphorylated 
nsP3 was infectious, but the level of RNA 
synthesis was signifi cantly decreased. 
The mutant virus pathogenicity in mice 
was also greatly reduced (Vihinen at al., 
2001). 
2. 2. 3. NsP2 
NsP2 (SFV 799aa) has multiple roles 
in RNA replication and polyprotein 
processing. It has two distinct functional 
domains: the N-terminal part contains 
sequence motifs typical for RNA and 
DNA helicases, and the C-terminal part 
is homologous to papain-like cysteine 
proteinases (Gorbalenya et al, 1991; 
Koonin and Dolja, 1993). The nucleoside 
triphosphatase (NTPase) and RNA helicase 
activities were verifi ed by biochemical 
studies (Rikkonen et al., 1994; Gomez de 
Cedron at al., 1999). Both activities were 
associated with the N-terminal part (1-479 
aa) of nsP2. Additionally, the N-terminal 
half of nsP2 has been identifi ed as an 
RNA triphosphatase, catalyzing the initial 
step of the virus-specifi c mRNA capping 
reaction (Vasiljeva et al., 2000). The C-
terminal domain of nsP2 (residues 458-
799 for SFV) functions as the nonstructural 
proteinase (Strauss and Strauss, 1994; 
Vasiljeva et al., 2001). The activity is 
responsible for all proteolytic cleavages 
in the polyprotein processing, albeit with 
different effi ciencies. Site between nsP3 
and nsP4 (3/4) was cleaved most readily, 
site 1/2 fairly effi ciently and site 2/3 poorly. 
A mutation in the catalytic site of nsP2 
protease (Cys478) abolished the proteolysis 
of nonstructural polyprotein (Vasiljeva et 
al., 2001). NsP2 plays also a role in the 
regulation of subgenomic RNA synthesis. 
Experiments with ts mutants demonstrated 
that nsP2 directly or indirectly binds to 
the 26S RNA promoter. The proteolytic 
activity of nsP2 also regulates the levels of 
production of minus strands vs plus strands 
(Sawicki and Sawicki, 1993; Suopanki et 
al., 1998). NsP2 has multiple locations in 
cells. Only part of nsP2 is assembled with 
other nsPs in the replication complex. In 
infected cells, about half of the protein 
is found in the nucleus and the rest is 
distributed throughout the cytoplasm 
(Peränen at al., 1990). When expressed 
alone, nsP2 is localized exclusively in the 
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mapped by mutagenesis to the C-terminal 
domain of nsP2 (Rikkonen at al., 1992). 
2. 2. 4. NsP1
Both genomic and subgenomic RNAs 
of alphaviruses have m7G(5′)ppp(5′)N 
(cap0 structure) at their  5′end. NsP1 
(SFV 537 aa) is a capping enzyme, which 
catalyzes the formation of cap-structure. 
The N-terminal half of nsP1 contains the 
conserved domain, which is found in all 
alphavirus-like superfamily members 
(Rozanov et al., 1992). NsP1 possess two 
enzymatic activities. Firstly, it acts as a 
methyltransferase catalyzing the transfer 
of a methyl group from S-adenosyl-
methionine (AdoMet) to GTP (Mi and 
Stollar, 1991; Laakkonen at al., 1994). 
Secondly, it is a guanylyltransferase 
that transfers the m7GMP to the 5′ 
terminus of RNA via the formation of 
intermediate complex nsP1-m7GMP 
(Ahola and Kääriäinen, 1995). NsP1 
catalyzes both capping reactions in a 
different manner than cellular enzymes, 
where guanylyltransferase fi rst transfers 
the GMP to the mRNA and only after 
that methylation at position 7 takes place 
(Ahola and Kääriäinen, 1995, Shuman, 
1995, Shuman, 2001). In both pathways, 
these reactions are preceded by RNA 5′ 
triphosphatase, which removes the 5′ γ-
phosphate from the nascent viral RNA 
chain. NsP2 has been demonstrated to 
catalyze this reaction in alphaviruses 
(Vasiljeva et al., 2000).
NsP1 is the membrane anchor for the 
replication complex (this study II; Salonen 
et al., 2005). It is tightly associated with 
membranes both in alphavirus infected 
cells and when expressed alone. The tight 
binding was due to palmitoylation of 
cysteine residues 418-420 (Peränen et al., 
1995, Laakkonen et al., 1996, Ahola et al., 
2000). When these residues were mutated 
to alanines, nsP1 was still membrane-
associated and enzymatically active. 
However, it could be released from the 
membranes by a high salt treatment. Thus, 
the elimination of palmitoylation converted 
nsP1 from an “integral” to a “peripheral” 
membrane protein (Laakkonen at al., 
1996). Another mechanism responsible for 
membrane association is a direct interaction 
of nsP1 with the anionic phospholipids. 
The interaction is mediated by amino acids 
245-264, with both positively charged and 
hydrophobic residues required for binding 
(Ahola et al., 1999; Lampio et al., 2000). 
The nsP1 polypeptide segment (245-264) 
is highly conserved within alphavirus-
like superfamily (Rozanov et al., 1992) 
and could play a role in the membrane 
association of other superfamily members. 
      
3. HEPATITIS E VIRUS
3. 1. General aspects of infection
Hepatitis E, previously known as enterically 
transmitted non-A, non-B hepatitis, is 
an infectious viral disease with clinical 
and epidemiological features of acute 
hepatitis. It is transmitted by the fecal-
oral route mainly through contaminated 
drinking water. The fi rst documented 
outbreak of hepatitis E occurred in New 
Delhi, India, in 1955 and consisted of 29 
000 cases (Purcell and Emerson, 2001). 
Hepatitis E virus is the major causative 
agent of acute hepatitis in young adults 
living in developing countries with poor 
sanitary conditions and high population 
density. The mortality rate among hepatitis 
E patients is usually 1-3 %, but it can reach 
up to 20% for infected pregnant women, 
especially during the third trimester (Tam 
et al, 1999; Worm et al., 2002). Hepatitis 
E is also diagnosed in industrialized 
countries, although most of the cases are 
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There is also a possibility for zoonotic 
reservoir, since the virus is found in both 
wild and domestic animals, e.g. non-human 
primates, pigs, cows, chickens, sheep, 
goats and rodents (Meng, 2000; Favorov 
et al., 2000). The fi rst animal strain of 
HEV was isolated from a pig in the United 
States (Meng et al., 1997). Cross-species 
infections of HEV between swine and 
nonhuman primates were experimentally 
demonstrated, suggesting that hepatitis E 
may be a zoonotic disease (Meng et al., 
1998).
Humans are the natural hosts for 
hepatitis E virus. Several primate species, 
including chimpanzees, cynomolgus 
macaques, rhesus monkeys, tamarins 
and African green monkeys, are found 
to be susceptible to HEV infection and 
have served as experimental models for 
hepatitis infection (Bradley et al., 1987; 
Purcell and Emerson, 2003). HEV enters 
the host by oral ingestion and reaches 
the liver by unknown mechanisms. HEV 
replicates primarily, if not exclusively, 
in hepatocytes, although, several studies 
in rats and swine model suggested that 
extrahepatic tissues such as peripheral 
blood monocytes, spleen, lymph nodes 
and small intestine may be involved in 
HEV replication (Maneerat et al., 1996, 
Williams et al., 2001). Hepatitis E infection 
usually becomes apparent within 2-9 
weeks of exposure, the average incubation 
period being 6 weeks. Early symptoms of 
infection, such as fever, nausea, vomiting, 
diarrhea, headache and abdominal 
enlargement can occur a week before 
the onset of jaundice. Fecal excretion of 
virus particles begins during this period, 
refl ecting replication of viruses within 
hepatocytes. Viremia usually precedes the 
major peak of alanine aminotransferase 
activity (Tam et al, 1999). Anti-HEV IgM 
appears in the serum of the patients early 
during the infection and remains detectable 
for 2-3 months. Anti-HEV IgG antibodies 
can be detected after IgM response and 
usually persist for years. Generally, the 
period of recovery from hepatitis E can 
take up to 14 weeks. HEV infection 
never progress to chronicity (Purcell and 
Emerson, 2001).
3. 2. Classifi cation and genetic 
heterogeneity
From 1988 to 1998, based on 
physiochemical properties, hepatitis E 
virus was classifi ed into the Caliciviridae 
family. However, sequence comparison 
and genome organization analysis revealed 
little, if any, homology between HEV and 
caliciviruses. At present, HEV is classifi ed 
in to the new family Hepeviridae as a 
separate genus Hepevirus (Emerson et 
al., 2004a). Phylogenetic analysis of 
HEV nonstructural regions shows that it 
is related more closely to the alphavirus-
like superfamily, in particular to rubella 
virus and Beet necrotic yellow vein virus 
(BNYVV), a plant benyvirus (Koonin et 
al., 1992).
First sequence of entire HEV genome 
from an outbreak in Myanmar (Burma) 
became available more than a decade ago 
(Reyes et al., 1990; Tam et al., 1991). 
The genomes of several HEV strains 
from different parts of the world became 
available since, e.g. Pakistan (Tsarev et al., 
1992), China (Bi et al., 1993) and Mexico 
strains (Huang at al., 1992). However, the 
majority of HEV isolates have only been 
sequenced partially. Sequence comparisons 
and phylogenetic analyses show that the 
genome sequence of HEV is quite stable. 
The nucleotide identity of strains isolated 
in single outbreak is very high (Arankalle et 
al., 1999). However, the genome of strains 
isolated from geographically distinct 
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locations is generally more diverse. It has 
been suggested that HEV isolates segregate 
into four major genotypes: Genotype 1-
including the isolates from South-East 
Asian (Burma, India), North and Central 
Asian (China, Pakistan, Kyrgyzstan and 
India) and North African strains; Genotype 
2-comprising a single North American 
(Mexico) isolate; Genotype 3-consisting 
of the US human and swine isolates; and 
Genotype 4-including several isolates 
from China and most isolates from Taiwan 
(reviewed in Wang and Zhuang, 2004). 
Of these, the Mexican isolate cloned 
from the Telixtac outbreak is the most 
divergent genetically. The Asian strains 
are well-conserved among themselves, 
with nucleotide sequence identity between 
93 and 100% in the coding regions and 
amino acid sequence identity between 
98 and 100 % (Tam et al., 1999). In spite 
of the geographical diversity of HEV 
isolates, only one serotype is recognized 
(Schlauder and Mushahvar, 2001). That 
suggests a possibility for the development 
of a broad range vaccine against hepatitis 
E infection.
3. 3. Virion structure and genome 
organization
HEV is an icosahedral, non-enveloped 
particle with spike-like protrusions visible 
on the surface of the virus. The average 
diameter of particles is about 32nm 
(Balayan et al., 1983). The fact that HEV 
can survive in the gastrointestinal tract 
suggests that the virus is relatively stable to 
acid and mild alkaline conditions (Purcell 
and Emerson, 2001). However, insuffi cient 
amount of virus has been available for 
purifi cation and direct chemical analysis 
to yield reliable information. Recent 
studies show that recombinant hepatitis 
E virus capsid protein self-assembles into 
virus-like particles (VLP), when expressed 
by the use of a recombinant baculovirus 
vector in an insect cell system (Xing et 
al., 1999; Li at al., 2001; Maloney et al., 
2005). The 60 copies of a single capsid 
protein cluster as 30 dimers into a T=1 
lattice. The recombinant particles share 
morphological and antigenic properties 
with native virions that, together with 
high levels of production, make rHEV 
particles an ideal candidate for a hepatitis 
E vaccine.
Hepatitis E virus genome is enclosed 
within a capsid and contains a single-
stranded, positive-sense, polyadenylated 
RNA molecule of approximately 7.2 kb 
in length (Fig. 3).  The genome of the 
prototype strain of HEV, recovered from 
the outbreak in Myanmar, consists of 5′ 
noncoding (NC) region of 27 nucleotides, 
followed by an ORF1 of 5079 base 
pairs, which is postulated to encode the 
nonstructural polyprotein. A second ORF 
(ORF2) is separated from ORF1 by 38 nt 
and consists of 1980 nucleotides. A 65-
nucleotide noncoding region is contiguous 
MT Y PRO? X HEL POL
ORF3 (nt5106-5474)
CP
ORF1 (nt 28-5106) ORF2 (nt 5147-7126)
Anm7G
5′ NTR
(nt 1-27)
3′ NTR
(nt 7127-7194)
Figure 3. Organization of HEV genome. The m7G cap and polyA tail are shown at the 5′ and 
3′ terminus, respectively. The methyltransferase (MT), Y, protease (PRO), X, helicase (HEL), 
RNA-dependent RNA polymerase (POL) and capsid (CP) domains are indicated.
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with the termination of ORF2 and is 
terminated by a 3′ stretch of 150-200 
adenosine residues. A third ORF (ORF3), 
369 nucleotides in length, overlaps ORF1 
by 1 nucleotide at its 5′ end and extends 
328 nucleotides into ORF2. Thus, the HEV 
genome consists of three ORFs and utilizes 
all three of them (Tam et al., 1991).
3. 3. 1. ORF1
The functions of proteins encoded 
by hepatitis E virus genome have 
been predicted by computer-assisted 
comparative analysis of HEV sequences 
with proteins of other positive-strand RNA 
viruses.  Starting from the 5′ end of ORF1 
the following conserved motifs have 
been identifi ed: (i) a methyltransferase, 
suggesting that the 5′ end of the viral 
genome is capped; (ii) an Y domain of 
unknown function, found also in rubella 
virus; (iii) a papain-like cysteine protease, 
related to protease of alphaviruses and 
rubella virus; (iv) a proline-rich region 
that is thought to be important for the 
fl exibility of the molecule and that contains 
a hypervariable sequence motif; (v) an X 
domain of unknown function; (vi) an RNA 
helicase possibly promoting the unwinding 
of RNA required for genome replication 
and transcription; (vii) an RNA-dependent 
RNA polymerase (Koonin at al, 1992).
The molecular biology of HEV 
replication is not well understood, mainly 
because HEV does not grow effi ciently 
in cell culture. Much of the knowledge 
concerning HEV has been obtained through 
the expression of recombinant proteins in 
vitro. So far, studies led to identifi cation 
of two active viral enzymes: an RNA-
dependent RNA polymerase (Agrawal 
et al., 2001) and a capping enzyme (this 
study).
Putative motive for a methyltransferse 
is located in the N-terminal part of the 
genome of all alphavirus-like family 
members, being the hallmark of this 
group of viruses (Rozanov et al., 1992). 
The ability of a monoclonal antibody to 
recognize 7-methylguanosine (m7G) in 
RNA extracted from virions of different 
HEV genotypes suggested that HEV RNA 
is capped (Kabrane-Lazizi at al, 1999). The 
enzymatic activity of methyltransferase 
was experimentally demonstrated for N-
terminal fragment of HEV polyprotein, 
produced in insect cells using recombinant 
baculovirus vector (I). This study describes 
the properties of HEV as a capping 
enzyme, which catalyzes both guanine-7-
methyltransferase and guanylyltransferase 
activities required for capping of viral 
mRNAs (see Results).
The RNA-dependent RNA polymerase 
activity of HEV has been demonstrated 
for a 63kDa protein, expressed in E.coli. 
This recombinant HEV RdRp was able 
to synthesize RNA in vitro using 3′ end 
HEV RNA with poly(A) stretch as the 
template in a primer-independent manner 
(Agrawal et al., 2001). The polarity of the 
newly synthesized product was confi rmed 
to be negative. The same study showed 
the specifi c binding of HEV RdRp to the 
3′ end of the viral genome. This region 
with a number of stem-loop structures at 
the extreme 3′ end shows a high degree 
of nucleotide conservation among several 
viral isolates and is believed to play 
a crucial role in the initiation of viral 
replication (Agrawal et al., 2001; Emerson 
et al., 2001).
The replication cycles of many 
positive-strand RNA animal viruses 
studied include a proteolytic processing of 
a polyprotein precursor by virus-encoded 
proteases (Gorbalenya et al., 1991; Ropp 
et al., 2000). The presence of papain-like 
cysteine protease in hepatitis E virus was 
shown by computer-assisted analysis, 
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although the amino acid similarity 
between the putative HEV protease and 
other viral PCPs was weak (Koonin et al., 
1992). Contradictory results were reported 
concerning the processing of the HEV 
ORF1 polyprotein (Ansari et al., 2000; 
Ropp et al., 2000; Panda et al, 2000). 
We have studied this matter further (see 
Results and Discussion).
3. 3. 2. ORF2
ORF2 codes for the major structural 
protein (pORF2) of 660 amino acids (88 
kDa). The N-terminal part of pORF2 
contains N-linked glycosylation sites and 
a putative endoplasmic reticulum (ER)-
directing signal peptide. It is synthesized 
as a precursor which is cotranslationally 
translocated into the ER, where it is 
processed into the mature protein through 
signal sequence cleavage (Jameel at al., 
1996). This protein is also glycosylated in 
the ER at all three possible glycosylation 
sites, which were mapped by mutational 
analysis to asparagines residues (Asn137, 
Asn310 and Asn562). Interestingly, the 
pORF2 amino-terminal signal sequence 
and all three N-linked glycosylation sites 
are universally conserved in all isolates 
of human HEV, suggesting functional 
signifi cance for glycosylation (Zafrullah 
et al., 1999). Recent study showed that 
ORF2 encoded protein has an RNA 
binding activity (Surjit et al., 2004). The 
ORF2 protein can interact specifi cally 
with the 5′ end of the HEV genome. 
Particularly, a 76-nucleotide region at the 
5′ end of the viral RNA is responsible for 
binding the ORF2 protein. Remarkably, 
this 76-nt region includes the 51-nt HEV 
sequence conserved among alphaviruses 
(Niesters and Strauss, 1990). Structural 
proteins of positive-strand RNA viruses are 
known to use their RNA binding activity 
for promotion of viral replication and 
packaging of its genome into the capsid 
during viral assembly. Since pORF2 is 
the major capsid protein, it is the most 
likely candidate to bind the genomic RNA 
for its encapsidation (Surjit et al, 2004). 
The ORF2 protein is also being explored 
as a potential vaccine against hepatitis E 
(discussed later in this study).
3. 3. 3. ORF3
Open reading frame 3 encodes a protein 
of 13.5 kDa (called pORF3) with 
unknown function. The ORF3 protein is 
phosphorylated at a single serine residue 
(Ser80) by a cellular mitogen-activated 
protein kinase (MAPK) (Zafrullah et al., 
1997). Interestingly, this serine residue is 
conserved among all HEV isolates with 
the exception of more divergent Mexican 
isolate (Huang et al., 1992). In addition, 
pORF3 contains a C-terminal proline-rich 
region that interacts with Src homology 3 
(SH3) domains of several cellular proteins 
involved in signal transduction (Korkaya 
et al., 2001). Furthermore, ORF3 protein 
can activate an extracellular signal-
regulated kinase (ERK), a member of the 
MAPK superfamily (reviewed in Panteva 
et al, 2003; Kar-Roy et al., 2004). The 
ORF3 encoded protein has been shown 
to self-associate into homodimers and to 
interact with full-length, nonglycosylated 
form of the capsid protein (Tyagi et al., 
2001; Tyagi et al., 2002). These results 
clearly indicate that pORF3 must have 
activities that involve interaction with 
host cell proteins. Recent study by Tyagi 
and colleagues (2004) demonstrated 
that ORF3 protein specifi cally interacts 
with α1-microglobulin/bikunin precursor 
(AMBP) and enhances its export from 
the hepatocytes. AMPB is a liver-
specifi c protein that is processed into 
two mature proteins, α1-microglobulin 
and bikunin, which both possess general 
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immunosuppressive properties (Tyagi et 
al., 2004). Additionally, pORF3 associates 
with the cytoskeleton and this association 
requires the N-terminal hydrophobic 
domain (aa 1-32) of the protein (Zafrullah 
et al., 1997). The ability of pORF3 to 
form a complex with the major capsid 
protein pORF2 suggests that one possible 
function of pORF3 within the HEV life 
cycle is to serve as a cytoskeletal anchor 
at which pORF2 can assemble the viral 
nucleocapsid. However, the mechanisms 
of viral assembly and transport are not 
known at present.
3. 4. Experimental propagation, 
expression and replication
The replication and transcription strategy 
of HEV are poorly understood, mainly 
because HEV does not replicate effi ciently 
in the cell culture. Nothing is known 
about attachment, entry and uncoating 
of the virus. The mechanisms of virus 
assembly and transport from the host cell 
also remain to be determined. The fact that 
HEV replicates naturally in human and 
monkey hepatocytes, sets limitations to 
utilization of this system due to diffi culties 
associated with animal experimentation. 
Due to the absence of cell culture system 
and a small animal model, the knowledge 
concerning HEV on the molecular level 
has been obtained through the expression 
of recombinant proteins. HEV genes have 
been cloned and expressed in bacterial, 
animal cell, baculoviral and yeast 
expression systems (reviewed in Worm et 
al., 2002). 
An in vitro propagation and production 
of HEV from the primary hepatocytes 
of experimentally infected cynomolgus 
macaques has been reported (Tam et 
al., 1996, Tam et al., 1997).  Both the 
positive-sense and the negative strands of 
HEV RNA were detected in hepatocytes, 
indicating that replication proceeds via 
synthesis of intermediate negative-strand 
RNA, which in turn serves as a template 
for synthesis of more genomic RNAs, as 
well as subgenomic RNAs. At least two 
subgenomic polyadenylated RNAs of 
2 and 3.7 kb were identifi ed (Tam et al., 
1991, Yarbough et al., 1991). However, 
replication in this system is ineffi cient, 
since reverse transcription-PCR is required 
to monitor it. In another study, a full-
length HEV cDNA clone was constructed 
and used for in vitro transcription of 
RNA, which was transfected into HepG2 
cells. Viral replication was detected for 6 
passages (33 days) with strand-specifi c 
PCR (Panda et al., 2000). 
In vitro synthesized transcripts from 
two full-length cDNA clones of the Sar-
55 strain (Pakistan) differing by two 
nucleotides, were able to initiate infection 
in rhesus monkeys and chimpanzees 
after intrahepatic inoculation (Emerson 
et al., 2001). Only capped transcripts 
infected chimpanzees, indicating that 
cap is required for viral viability. This 
study demonstrated that a single mutation 
located at nucleotide 7106 at the 3′ end of 
the capsid gene abolished the infectivity of 
a recombinant genome for rhesus monkeys 
and attenuated it for chimpanzees. The 
attenuation occurred even though the 
mutation did not change the encoded amino 
acid, suggesting that the mutation must be 
located within a cis-reacting element. This 
single nucleotide mutation is located in a 
stem-loop structure predicted by Agrawal 
et al. (2001), which is important for binding 
of the RNA polymerase.     
Recently, construction of HEV 
replicon from the infectious cDNA clone 
of the Sar55 strain has been reported 
(Emerson et al., 2004b). In this replicon 
the ORF2 and ORF3 genes were replaced 
with the green fl uorescent protein (GFP), 
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enabling the detection of the replication 
by the fl uorescence microscopy. The 
transfection with capped transcripts resulted 
in the appearance of green fl uorescent 
cells at 2 to 4 days post transfection. As a 
parallel experiment various cell lines were 
transfected with the full-length genome, to 
determine the degree of permissiveness for 
HEV genomic replication. Four cell lines 
out of seventeen supported the replication: 
three human liver cell lines (Huh-7, HepG2 
and PLC/PRF/5) and human intestinal 
cell line Caco-2. Neither the replicon nor 
the viral genome, were able to replicate 
in any of the nonprimate cells tested, 
suggesting that species-specifi c factors 
may be required. Similar numbers of cells 
were positive when transfected either with 
full-length genome or with GFP replicon, 
the effi ciency of transfection staying 
consistently under 15 %. Interestingly, 
the single mutation at nt 7106 which had 
attenuated Sar55 for nonhuman primates, 
substantially reduced the effi ciency of 
replication, when introduced into the 
replicon (Graff et al., 2005). Similar HEV 
replicon with fused reporter genes was 
constructed by Thakral and colleages 
(2005). The replication of hepatitis E virus 
genome in HepG2 cells was detected until 
the seventh passage (50 days). Despite 
numerous efforts, an effi cient system to 
study HEV replication still remains to be 
developed.
3. 5.  Vaccine candidates against 
hepatitis E 
There is no specifi c treatment for hepatitis 
E infection at present. The development 
of an attenuated or killed vaccine is not 
currently possible, because an effi cient 
cell culture system to grow the virus has 
not been discovered. Therefore, various 
recombinant proteins have been explored as 
vaccine candidates (reviewed in Emerson 
and Purcell, 2001). ORF2 encodes the 
major capsid protein, and it has been the 
focus of the vaccine development. Many 
different ORF2 antigens have been shown 
to induce antibody, however in most of the 
cases they were not neutralizing antibodies. 
Only one neutralization epitope has been 
identifi ed so far. This epitope is located 
between amino acids 578 and 607 of the 
capsid protein (Schofi eld et al., 2000; 
Meng et al., 2001).
The fi rst candidate vaccine consisted 
of a recombinant fusion protein comprising 
tryptophan synthetase and the carboxyl 
two thirds of the putative capsid protein of 
Burmese strain, expressed in E. coli (Purdy 
et al., 1993). Two cynomolgus monkeys 
vaccinated with this protein were protected 
against disease following challenge with 
the homologous virus, and a third monkey 
was protected when challenged with the 
heterologous Mexican strain.
Truncated recombinant capsid 
proteins expressed from baculovirus 
vectors in insect cells have been studied 
more extensively. A recombinant 50 kDa 
ORF2 protein of Myanmar (Burmese) 
strain expressed in insect cells was 
secreted into the medium and assembled 
into virus-like particles (Li et al., 1997). 
These VLPs induced both systemic and 
mucosal anti-HEV response in mice when 
administered orally (Li et al, 2001). In a 
recent study cynomolgus monkeys were 
orally inoculated with purifi ed VLPs. They 
developed protection against infection or 
developing hepatitis, when challenged 
with native HEV by intravenous injection 
(Li et al., 2004). These results suggest that 
recombinant HEV VLPs are a signifi cant 
candidate for an oral hepatitis E vaccine 
(Maloney et al., 2005).
So far, only one HEV vaccine 
candidate has progressed to the stage of 
clinical trials. A recombinant baculovirus-
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expressed vaccine, containing amino acids 
112-607 of the 660-aa protein encoded 
by ORF2 of a Pakistan strain, has been 
developed at the National Institute of 
Health, USA (Emerson and Purcell, 2001). 
This candidate vaccine contains previously 
identifi ed immunodominant neutralization 
epitope located between aa 458-607 in 
ORF2 protein (Zhou et al., 2005). It has 
just entered a phase II-III effi cacy trial 
in Nepal, where hepatitis E is endemic 
(Purcell et al., 2003; Wang and Zhuang, 
2004).
4. mRNA CAPPING
Eukaryotic pre-mRNAs are transcribed 
by RNA polymerase II (Pol II) and 
undergo several processing events 
before becoming mature messenger 
RNA. These modifi cations, including 5′ 
capping, splicing and polyadenylation, are 
completed in the nucleus before mRNA is 
transported to the cytoplasm and translated. 
Cap formation occurs co-transcriptionally 
during the initial stages of elongation, 
when the nascent RNA transcript is only 
25-30 nucleotides long (Shatkin and 
Manley, 2000). Co-transcriptional capping 
is facilitated by recruitment of the capping 
enzyme machinery to the phosphorylated 
C-terminal domain of RNA polymerase II, 
a domain that serves as a “platform” for 
macromolecular assemblies that regulate 
mRNA synthesis and processing (Cho 
et al., 1997, Shuman, 1997). The 5′ cap 
A
B
(1) pppN1N2N3... ppN1N2N3... + Pi
(2) GTP + E GMP-E + PPi
(3) GMP-E + ppN1N2N3...
m7GpppN1N2N3... + AdoHcy(4) GpppN1N2N3... + AdoMet
GpppN1N2N3... + E
Figure 4. Structure and synthesis pathways of the mRNA cap (modifi ed from Gu and Lima, 
2005). A) chemical structure. The cap consists of N7-methyl guanosine linked by an inverted 
5′-5′ triphosphate bridge to the fi rst nucleoside of the mRNA chain (base N can be adenine, gua-
nine, cytosine or uracil. B) enzymatic synthesis of the mRNA cap in eukaryotic cells and DNA 
viruses.  See text for references and explanations.
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structure plays an essential role in the 
mRNA cycle. It is required for accurate 
and effi cient splicing and nuclear export 
of mRNAs (Shuman, 1995). Cap structure 
is essential for translation of most 
eukaryotic mRNAs, as it is recognized 
by the eukaryotic initiation factor eIF4E. 
Cap also increases mRNA stability by 
protecting it against 5′→3′ exonucleotic 
degradation (Furuichi and Shatkin, 2000).
Capping occurs by a series of three 
enzymatic reactions (Fig. 4). First, the 5′ 
triphosphate end of the nascent pre-mRNA 
transcript is hydrolysed to a diphosphate 
by RNA 5′ triphosphatase (TP). Second, 
the diphosphate RNA end is capped with 
GMP by RNA guanylyltransferase (GT). 
Finally, the GpppN cap is methylated by 
RNA (guanine-N7) methyltransferase 
(MT), completing the m7GpppN, or cap0, 
structure (Banerjee, 1980). Methylation of 
the cap generally becomes more complex 
as organisms evolve. For example, 
in higher eukaryotes mRNAs may be 
further modifi ed by 2′-O-methylation of 
the riboses of the fi rst and second bases 
(cap1 and cap2, respectively). Transfer 
of GMP from GTP to the 5′-diphosphate 
terminus of RNA occurs in a two stage 
reaction involving a covalent enzyme-
GMP intermediate. The GMP is linked 
to the enzyme through a phosphoamide 
(P-N) bond to the ε-amino group of a 
lysine residue within a conserved KxDG 
motif (reviewed in Shuman and Schwer, 
1995; Shuman and Lima, 2004). Although 
mRNA cap structures are conserved in 
all eukaryotic organisms that have been 
examined so far, the organization of 
genes, subunit composition and catalytic 
mechanisms of the component enzymes 
differ signifi cantly among species 
(reviewed in Shuman, 2001; Gu and Lima, 
2005). This diversity makes RNA capping 
an attractive target for drug design.
4.1. Viral and cellular capping enzymes
The structures and mechanisms of the 
triphosphatase and guanylyltransferase 
components have been under intensive 
study during the past decade, leading to 
several high resolution crystal structures 
of viral, fungal and mammalian capping 
enzymes (Håkansson et al., 1997; Lima et 
al, 1999; Changela et al., 2001; Fabrega 
et al., 2003; Sawaya and Shuman, 2003). 
The guanine-N7-methyltransferase is the 
least understood component of the capping 
apparatus. Recently, the X-ray structure of 
the cellular cap methyltransferase Ecm1 
in complex with AdoMet, AdoHcy and 
the cap guanylate has been determined 
(Fabrega et al., 2004).
Viruses adopt various types of 
strategies for their parasitic replication 
and proliferation in infected cells. With 
a few exceptions, viral mRNAs contain 
the same cap structure as cellular mRNAs 
(Furuichi and Shatkin, 2000). Therefore, 
viruses have played a signifi cant role in 
defi ning the structure of mRNA cap and 
the biochemistry of cap formation. 
The enzymes responsible for capping 
have been initially isolated from vaccinia 
virus, a large DNA virus that replicates 
within the cytoplasm of the infected 
cells (Martin and Moss, 1975; 1976). 
Vaccinia virus mRNA capping enzyme 
is a multifunctional protein with RNA 
triphosphatase, RNA guanylyltransferase 
and methyltransferase activities. The 
protein is a heterodimer of 95 kDa and 33 
kDa subunits encoded by the vaccinia virus 
D1 and D2 genes, respectively (Barbosa 
and Moss, 1978; Shuman and Morham, 
1990). The 95 kDa polypeptide contains 
both TPase and GTase, whereas the 33 
kDa subunit is required for RNA (guanine-
7) methyltransferase activity (Shuman and 
Moss, 1990). The guanylyltransferase 
component of the enzyme catalyzes two 
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sequential nucleotidyl transfer reactions 
involving a covalent enzyme – (lysyl-
GMP) intermediate. The active-site Lys260 
residue is situated within a sequence 
element KxDG, which is conserved 
among guanylyltransferases, and is also 
found, in addition to fi ve other conserved 
motifs, in DNA and RNA ligases (Cong 
and Shuman, 1993; Shuman and Schwer, 
1995). Sequence conservation suggests 
that the GT-dependent capping enzymes 
together with ATP- and NAD+-dependent 
DNA ligases, and ATP-dependent RNA 
ligases comprise a superfamily of covalent 
nucleotidyltransferases, which evolved 
from a common ancestral enzyme (Wang 
et al., 1997). Crystal structures of fi ve 
superfamily members highlight a common 
fold consisting of N-terminal nucleotidyl 
transferase domain and a C-terminal OB 
fold domain with typical fi ve-stranded 
antiparallel β-barrel and an α-helix 
(Shuman and Lima, 2004). The 330-amino 
acid Chlorella virus enzyme is the smallest 
guanylyltransferase known and most 
probably represents the minimal catalytic 
domain (Ho et al., 1996). Crystal structure 
of Chlorella virus guanylyltransferase in 
GTP-, lysyl-GMP- and GpppG-bound 
states revealed important conformational 
changes during substrate binding and the 
chemistry of the reaction, especially the 
opening and closing of the cleft between 
the nucleotidyl transferase and OB domains 
(Håkansson et al., 1997; Håkansson and 
Wigley, 1998). The capping enzyme must 
MT GT
MT
MT
GT
GT
TP
TP
TP
TP
MT/GT
GT/TP
Poxviruses
(Vaccinia)
FUNGI AND PROTOZOA
S. cerevisiae
E. cuniculi
T. brucei
PLANTS AND METAZOA
DNA VIRUSES
RNA VIRUSES
C. elegans
Arabidopsis thaliana
Chlorella virus
Alphaviruses
MT
Figure 5. Comparative scheme of mRNA capping apparatus in eukaryotes and viruses. MT-
methyltransferase domain, GT-guanylyltransferase domain, GT/MT-protein or domain possess-
ing both MT and GT activities, TP-RNA triphosphatase.
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be in closed conformation to catalyze 
formation of the enzyme-guanylate 
complex. An open guanylyltransferase 
confi guration is presumed to be required 
at three phases of the catalytic cycle: for 
GTP binding, for binding of ppRNA and 
for release of the capped RNA product 
(Håkansson et al., 1997). The reverse 
direction of the guanylyltransferase 
reaction is blocked by the addition of the 
methyl group to the 5′ guanine nucleoside 
by the guanine-7-methyltransferase. The 
vaccinia virus enzyme prefers mRNA 
substrates, but also catalyzes, albeit less 
effi ciently, methylation of GpppN, GTP, 
dGTP, GMP and guanosine (Martin and 
Moss, 1976).
Cellular capping enzymes are 
larger and structurally more complex. 
The enzymes that catalyze yeast mRNA 
capping are encoded by three separate 
genes, all essential for cell viability or 
growth. The RNA capping enzyme of 
yeast Saccharomyces cerevisiae exists as 
a heterodimeric, bifunctional complex of 
two polypeptides of 80 and 52 kDa. The 
RNA triphosphatase is encoded by the 80 
kDa subunit, whereas a 52 kDa subunit 
contains a guanylyltransferase activity (Itoh 
et al., 1984; Shibagaki et al., 1992). The 
fi rst metazoan gene coding for a capping 
enzyme was obtained in Caenorhabditis 
elegans (Takagi et al., 1997). In contrast 
to the yeast capping enzyme, the metazoan 
and the mammalian capping enzymes both 
contain a single polypeptide with an N-
terminal RNA triphosphatase domain and 
a C-terminal guanylyltransferase domain 
(Yue et al, 1997; Shuman, 2002).
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AIMS OF THE STUDY
1) To identify and characterize the enzyme responsible for capping of hepatitis E 
virus mRNA
2) To study the localization, membrane association and functions of  Semliki 
Forest virus non-structural polyprotein
3) To study expression, intracellular localization, membrane association and 
processing of hepatitis E virus replicase
4) To review existing antiviral compounds and consider novel potential targets
Aims of the Study
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MATERIALS AND METHODS
1. Cells and viruses 
The origin and cultivation of Modifi ed 
Vaccinia Ankara virus (MVA) and HeLa 
cells were described earlier (Wyatt et 
al., 1995 and II). Cultivation of the 
SFV prototype strain and BHK21 cells 
was done as descibed by Keränen and 
Kääriäinen (1974). Human hepatoma 
Huh-7 cells, kindly provided by R. 
Bartenschlager (University of Heidelberg, 
Germany), were cultivated as described 
in (Lohmann et al., 2003 and III). The 
origin and preparation of HEV cDNA 
constructs are described in article I. The 
Bac-to-Bac Recombinant Baculovirus 
system and the plasmid vector pFastBac1 
(Gibco BRL) were used for the expression 
of nonstructural proteins. Construction 
of the recombinant baculovirus clones 
expressing SFV and HEV non-structural 
proteins has been described in (Merits et 
al., 2001) and in article I, respectively. 
Baculoviruses were cultivated in High 
Five BTI-Tn-5B1-4 (Tn5) cells in High 
Five medium (Invitrogen) according to 
manufacturer′s instructions. 
2. Bacterial strains and plasmids 
Escherichia coli DH5α (Bethesda Research 
Laboratories) was used as a host for 
propagation of the plasmids and molecular 
cloning. The recombinant proteins were 
expressed in E.coli strain BL21(DE3) 
(Novagen). DNA manipulations were 
done according to standard procedures 
described in Sambrook and Russell 
(2001). The list of the plasmids used for 
HEV protein expression in this study is 
given in Table 1. 
3. Infection and transfection
To express nonstructural proteins in HeLa 
or Huh-7 cells, the cells were fi rst infected 
with 20 PFU of vaccinia virus (MVA) 
per cell. Virus stock was diluted into 
minimal essential medium supplemented 
with bovine serum albumin (MEM + 0.2 
% BSA). MVA-infected cells, expressing 
T7 RNA polymerase, were transfected 
with pSP73 plasmids. Transfections were 
done in OPTIMEM®  (Invitrogen) using 
Lipofectamine 2000 (Invitrogen) or 
ExGen500 (MBI Fermentas) transfection 
reagents according to manufacturer′s 
instructions. After six hours, the 
transfection mixture was replaced with 
cell-specifi c full medium and then treated 
as explained in II and III. BHK cells were 
infected using 50 PFU of SVF or 5-20 
PFU of recombinant adenovirus per cell. 
SVF- and adenovirus infected cells were 
overlaid with fresh medium after removing 
the virus inoculum and incubated as 
specifi ed in II. Insect cells were infected 
with recombinant baculoviruses (10 PFU/
cell) in High Five medium and incubated 
for 4 hours before changing medium to 
fresh one. Cells were collected at 44 hours 
post infection and treated as described in I.
4. Radioactive labelling and cell 
fractionation
S-adenosyl[methyl- 3H]methionine, 
[3H]palmitic acid, [35S]methionine and 
[α-32P]GTP (Amersham) were used as 
described in I, II and III. The post nuclear 
supernatant (PNS) fraction used in many 
experiments was prepared as follows: cells 
expressing non-structural proteins were 
collected by scraping into cold phosphate 
buffered saline (PBS) and pelleted at 250 
x g for 10 minutes. The cell pellet was 
resuspended in 5 volumes of hypotonic 
buffer (10 mM Tris-HCl, pH 8.0 and 10 
mM NaCl, supplemented with protease 
inhibitor cocktail; Roche), left on ice for 
15 min to swell and disrupted in a Dounce 
homogenizer with 40 strokes. PNS was 
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prepared by removing the nuclei and intact 
cells by centrifugation at 500 x g for 10 
minutes. For some experiments PNS was 
further centrifuged at 15 000 x g for 20 
minutes to obtain membrane (P15) and 
supernatant (S15) fractions.
5. Flotation analysis
Membrane association of nonstructural 
proteins was established by fl otation 
assay in a discontinuous sucrose gradient 
as described by Laakkonen et al. (1996). 
Briefl y, PNS fractions were adjusted 
to a fi nal concentration of 60 % (w/w) 
and layered on top of a 67 % sucrose 
cushion in polyallomer tubes. Samples 
were overlaid by 50 % and 10 % sucrose 
and ultracentrifuged over night at 
50 000 x g, during which cytoplasmic 
Table 1. HEV constructs used in this study.
membranes and membrane-associated 
proteins fl oat to the top of the tube. Nine 
fractions were collected from the top and 
immunoprecipitated with specifi c antisera 
as described below. Precipitates were 
analysed by SDS-PAGE followed by 
immunoblotting or autoradiography.
To study the mode of membrane 
association, the membranes from the top 
fractions were pooled, sedimented and 
resuspended in buffers containing 1 M 
KCl, 50 mM EDTA, or alkaline sodium 
carbonate at pH 11.5 or 12. Membranes 
were resedimented and analyzed together 
with the respective supernatants by SDS-
PAGE and Western blotting to see if the 
treatment could release the protein from 
the membranes (I and II).
CONSTRUCT DESCRIPTION REFERENCE 
pGEM3P110 aa 1-979 of HEV ORF1, pGEM3 vector, T7 promoter, prokaryotic 
expression 
III
pET30aHEVORF1 full-length sequence of HEV ORF1, pET30a(+) vector, T7 promoter, 
prokaryotic expression 
III
pBATP50 aa 1-464 of HEV ORF1, pBAT vector, T7 promoter, prokaryotic 
expression 
I
Peränen et al., 1996
pET21aHEVX-HEL aa 779-1209 of HEV ORF1, pET21a(+) vector, T7 promoter, 
prokaryotic expression 
III
pET21aHEVPOL aa 1179-1693 of HEV ORF1, pET21a(+) vector, T7 promoter, 
prokaryotic expression 
III
pSP73ORF1 full-length sequece of HEV ORF1, pSP73 vector, T7 promoter, 
eukaryotic expression 
III
pSP73MT496 aa 1-496 of HEV ORF1, pSP73 vector, T7 promoter, eukaryotic 
expression 
III
pSP73MT712 aa 1-712 of HEV ORF1, pSP73 vector, T7 promoter, eukaryotic 
expression 
III
pSP73P110 aa 1-957 of HEV ORF1, pSP73 vector, T7 promoter, eukaryotic 
expression 
III
pSP73X-HEL-POL aa 775-1693 of HEV ORF1, pSP73 vector, T7 promoter, eukaryotic 
expression 
III
pSP73X-HEL aa 775-1206 of HEV ORF1, pSP73 vector, T7 promoter, eukaryotic 
expression 
III
pSP73POL aa 1206-1693 of HEV ORF1, pSP73 vector, T7 promoter, eukaryotic 
expression 
III
AcP110 aa 1-979 of HEV ORF1, pFastBac1 vector, polyhedrin promoter, 
eukaryotic expression 
I
unpublished
AcMT361 aa 1-361 of HEV ORF1, pFastBac1 vector, polyhedrin promoter, 
eukaryotic expression 
unpublished
AcMT496 aa 1-496 of HEV ORF1, pFastBac1 vector, polyhedrin promoter, 
eukaryotic expression 
unpublished
AcMT589 aa 1-589 of HEV ORF1, pFastBac1 vector, polyhedrin promoter, 
eukaryotic expression 
unpublished
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6. Antisera and cell-staining reagents
The preparation of polyclonal rabbit and 
guinea pig antisera against SFV proteins 
was described previously (Kujala et al., 
2001). The preparation and characterization 
of immune antisera against HEV proteins 
is described in detail (I and III). Briefl y, 
the proteins were produced in E.coli BL21. 
After cell breakage with a French press 
and centrifugation, the inclusion bodies 
were washed successively with buffer W 
(20 mM Tris-HCl, pH7.5, 10 mMEDTA, 
1 % Triton X-100, 500 mM NaCl, 2 M 
Urea) and PBS. Inclusion bodies were 
resuspended in PBS containing 0.5 % 
SDS. The immunization of rabbits and 
guinea pigs was carried out essentially as 
described previously (Kujala et al., 1999). 
A variety of organelle specifi c markers 
used for the characterization of cellular 
origin of HEV replicase listed in III.
7. Immunoprecipitation and 
immunoblotting
The immunoprecipitation of the proteins 
with specifi c antibodies was performed as 
described by Peränen et al., (1996). Samples 
(PNS, P15, S15 fractions, cell lysate or 
fl otation fractions) were denatured with 
1% SDS prior to immunoprecipitation and 
then incubated overnight in the presence 
of antibody in NET buffer (50 mM Tris-
HCl, pH 8, 150 mM NaCl, 1 % NP-40) 
at +4 °C. For enzymatic studies PNS was 
concentrated by immunoprecipitation 
under native conditions.
For immunoblotting, proteins were 
fi rst separated in SDS-PAGE gel and 
subsequently electrotransferred to a 
nitrocellulose membrane (Hybond-C-
extra, Amersham). Filters were blocked 
with 5% milk powder in PBS supplemented 
with 0.1 % Tween 20 (PBST) and probed 
with specifi c antibody in the same buffer. 
PBST was used for the washing and during 
incubation with secondary antibody (anti-
rabbit horseradish peroxidase, DAKO). 
The proteins were visualized using 
enhanced chemiluminescence (ECL) 
detection system (Amersham).
 
8. Enzyme assays
Guanine-7-methyltransferase activity 
was assayed as described in detail in 
I. The enzyme source, PNS from cells 
expressing nonstructural proteins, was 
immunoprecipitated under non-denaturing 
conditions using relevant antibody before 
assays. As a substrate we used GTP, 
and as a methyl donor we used AdoMet 
labeled with tritium in the methyl group 
(S-adenosyl[methyl-3H]methionine). The 
formation of a covalent guanylate complex 
was detected using [ -32P]GTP in the 
presence of unlabelled AdoMet and GTP. 
NTPase and RNA triphosphatase assays, 
used to study the enzymatic activities of 
ns polyproteins in II, were performed as 
described by Vasiljeva et al., 2000. Cell 
lysate, used as an enzyme source, was 
immunoprecipitated using relevant anti-
nsP antibody before the assay.
9. Immunofl uorescence microscopy    
For the microscopic analysis cells were 
grown over night on glass coverslips. HeLa 
cells were transfected with plasmids in 
combination with MVA infection (II, III) 
or infected with SFV or with adenoviruses 
(II). Huh-7 cells, used to study HEV 
proteins, were transfected using MVA-aided 
transfection system (III). Mock-infected 
and/or untreated cells were included as 
controls in all experiments. Cells infected 
with SFV or transfected using MVA were 
fi xed with 4 % PFA at 5 and 6 hours p.i, 
respectively (II and III). Expressions 
based on recombinant adenoviruses were 
fi xed after 24-28 hours of incubation 
(II). Cells were permeabilized using 
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0.1 % Triton X-100 before  subjecting 
to the antibody treatments. For inderect 
immunofl uorescence the cells were 
stained with anti-nsP (II), with anti-HEV 
antibodies (III) or in combination with 
organelle-specifi c markers. This was 
followed by treatment with species-specifi c 
secondary antibodies conjugated to either 
red-fl uorescent Alexa Fluor 568 or green-
fl uorescent Alexa Fluor 488 (Molecular 
Probes). The samples were analyzed with 
scanning confocal microscopy (Leica 
Microsystems).
Materials and Methods
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RESULTS
1. The RNA capping activity of HEV
The 5′ end of eukaryotic messenger RNA 
molecule contains a m7G(5′)ppp(5′)N cap 
structure, which is required for the effi cient 
initiation of translation and stability of 
mRNA. It has been predicted earlier that 
HEV belongs to the alpha-like superfamily 
of viruses, which contain a conserved 
methyltransferase or capping domain 
(Rozanov et al., 1992). Later, the presence 
of cap at the 5′ end of HEV RNA has been 
verifi ed experimentally (Kabrane-Lazizi 
at al, 1999). 
To study the capping reactions of 
hepatitis E virus, we have used constructs 
derived from the HEV Burma strain (I). A 
protein of 50 kDa (aa 1-464 of ORF1) was 
expressed in E.coli and used for production 
of HEV-specifi c antibody (designated 
α-MT). Since this protein was easily 
aggregated during expression in E.coli, 
a recombinant baculovirus expression 
system was used in further experiments. 
An N-terminal fragment of HEV ORF1 
protein (aa 1-979) was expressed in Tn5 
insect cells. The obtained protein of 
110 kDa was tested for the presence of 
predicted guanylyltransferase activity. 
The fl otation-purifi ed membranes from 
Tn5 cells expressing HEV P110 were 
incubated with [α-32P]GTP followed by 
immunoprecipitation with anti-HEV 
antibody, as described in Materials and 
Methods. The complex was detected as a 
radioactive band, but only in the presence 
of AdoMet. Two bands were visualized 
after immunoprecipitation: one of 110-
kDa designated as P110 and another band, 
presumably a proteolytic product of P110, 
with an apparent molecular mass of 80 kDa 
(P80) (I, Fig.4). The complex formation 
was specifi c for guanine nucleotides, 
GDP being the best substrate, followed by 
GTP. Tritium-labeled methyl group from 
S-adenosyl[methyl-3H]methionine was 
found in the covalent enzyme-guanylate 
complex, indicating that complex formation 
took place between P110 and m7GTP (I, 
Fig.5). No incorporation of methyl group 
to ATP, CTP or UTP was detected. In 
addition to AdoMet, the reaction required 
the presence of divalent cations (Mg2+ and 
Mn2+) (I, Fig.3). An inhibitory activity of 
several cap analogs on P110 was tested 
and, as expected, both m7GTP m7GDP 
had inhibited the incorporation of methyl 
group from AdoMet to GTP. The reaction 
was not inhibited by treatment with 
deoxycholate or Triton X-100. Therefore, 
immunoprecipitation in the presence of 
detergents was used to obtain signifi cantly 
pure preparation of enzymatically active 
P110 (I, Fig.5). Based on these results, 
we propose an order of HEV capping 
reactions:
(1) RNA triphosphatase
 pppN1N2N3…→ ppN1N2N3…+ Pi
(2) Guanine-7-methyltransferase
 GTP + AdoMet → m7GTP + AdoHcy
(3)  RNA guanylyltransferase
 m7GTP + P110 → m7GMP-P110 + PPi
(4) RNA guanylyltransferase
 m7GMP-P110 + ppN1N2N3…→ 
 m7GpppN1N2N3…+ P110
The capping enzyme of HEV fi rst acts 
as a methyltransferase, catalyzing the 
transfer of a methyl group from S-
adenosylmethionine to GTP to yield 
m7GTP. It then acts as a guanylyltransferase, 
transferring the methylated guanosine 
to mRNA via a covalent complex. Both 
capping reactions are virus-specifi c and 
differ from those described for eukaryotic 
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cells, but resemble those of the alphavirus-
like superfamily (see Discussion). 
To localize the activities more 
precisely, three shorter constructs, 
designated as MT361 (aa 1-361), MT496 
and MT589, were made and produced in 
insect cells with recombinant baculovirus 
vectors (Fig. 6). The shortest construct did 
not show any enzymatic activity, whereas 
MT496 and MT589 had similar properties 
as P110. Thus, sequence required for HEV 
methyltransferase and guanylyltransferase 
activities extends beyond the N-terminal 
361 amino acids.
2. Membrane association of HEV capping 
enzyme 
Membrane association of the N-terminal 
fragments of HEV ORF1 was studied 
by a fl otation assay, which separates 
membranes from soluble and aggregated 
components (see Materials and Methods). 
All N-terminal fragments of HEV ORF1: 
P110, MT361, MT496 and MT589 were 
expressed by recombinant baculovirus 
vector. All four proteins were associated 
with the cytoplasmic membranes fl oating 
to the top of the gradient (Fig. 7). This 
result suggests that the membrane-binding 
region is located within N-terminal 361 
amino acids, a region corresponding to 
alphavirus nsP1. 
To probe the mode of membrane 
association, the P15 fraction or the 
fl oated membrane fraction from Tn5 
cells expressing P110 was subjected to 
various treatments. HEV P110 was not 
released by high-salt or EDTA treatments, 
which releases most peripheral membrane 
proteins. P110 was quite tightly associated 
to the membranes and was only partially 
released by alkaline solutions at pH 12 
(data not shown). There was no evidence 
for palmitoylation in labelling experiments, 
indicating that this membrane association 
was not due to the palmitoylation of P110, 
as is the case for alphavirus nsP1 protein.
Membrane association of the HEV 
replicase was also studied using an in 
vitro translation system. No signifi cant 
binding was detected, when HEV ORF1 
and its truncated N-terminal derivatives 
were translated in the presence of 
liposomes containing anionic membrane 
phospholipids (data not shown).
P110 MT369 MT589MT496
A
B
IgG
Figure 6. Formation of enzyme-guanylate 
complex in Tn5 insect cells with Ac-HEV. A) 
Coomassie blue staining after immunopre-
cipitation of P15 fraction from baculovirus in-
fected Tn5 cells. B) Covalent complex formed 
after incubation of immunoprecipitated P110, 
MT496, MT589 with [α-32P]GTP in the pres-
ence of 100 μM of AdoMet.
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3. Intracellular distribution and proteo-
lytic processing of HEV nonstructural 
polyprotein
To study the proteolysis of HEV 
nonstructural polyprotein we made a 
plasmid expressing the full-length ORF1 
under the control of T7 promoter. HEV 
ORF1 was expressed in vitro using 
coupled transcription/translation system. 
A 186 kDa protein, the predicted size of 
the ORF1 primary translation product, 
was present after 30 minutes and was not 
increased signifi cantly during 90 minutes 
time course (III, Fig. 2). Two other faint 
bands of approximately 130 and 56 kDa 
were observed in addition to the full-size 
translation product. Immunoprecipitation 
with anti-HEV specifi c antibodies 
revealed that upper band of 130 kDa 
was an N-terminal fragment of HEV 
ORF1 and a lower band (56 kDa) was a 
C-terminal fragment (III, Fig. 2). The 
intensity of these two bands was variable 
in different experiments, and addition of 
cycloheximide or divalent cations did 
not have any effect on the course of the 
reaction (III, Fig. 3).
The expression of HEV ORF1 in 
vivo was carried out using a recombinant 
vaccinia virus-aided transfection. One 
strong band of 186 kDa was observed after 
a standard labelling period (1 to 4 hours) 
done 7 hours posttransfection (III, Fig. 
4). A number of lower faint bands were 
also detected. One of them was identifi ed 
by the immunoprecipitation as ~120 kDa 
N-terminal fragment of HEV ORF1. The 
result was reproduced in two cell lines: 
HeLa and Huh-7 human hepatoma cells. 
Prolonged labelling period (24 hours) 
did not have any effect on the expression 
pattern.
Localization of HEV nonstructural 
polyprotein inside the cell was 
studied by subcellular fractionation, 
immunofl uorescence analyses and double-
1 2 3 4 5 6 7 8 9
P110
MT361
MT496
MT589
sample ~60 % sucrose
50 % sucrose
10 % sucrose
67 % sucrose
Figure 7. Membrane association of HEV capping enzyme. Post-nuclear supernatant was 
subjected to fl otation in discontinuous sucrose gradient. Fractions were collected from the top 
and subjected to SDS-PAGE followed by immunoblotting with α-MT antibody. The top of the 
gradient is on the left.
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label confocal laser scanning microscopy 
(see Materials and Methods). Biochemical 
studies have shown that an N-terminal 
fragment HEV P110 expressed in insect 
cells was tightly membrane-associated 
and present in the mitochondrial pellet 
fraction P15 (I). Subsequent fl otation in a 
discontinuous sucrose gradient confi rmed 
tight membrane association of HEV P110. 
Similar result was obtained with a shorter 
fragment MT496 expressed under the 
same conditions (this study). When the 
full-length ORF1 was expressed in HeLa 
cells via vaccinia virus-aided transfection, 
the major pool of the polyprotein was also 
found associated with P15 membranes 
(III, Fig. 5). Further experiments revealed 
that more than half (54 %) of the protein 
was fl oating with the membranes in a 
sucrose gradient. Immunofl uorescense 
microscopy with HEV-specifi c antibodies 
confi rmed membrane association of HEV 
polyprotein. The full-length pORF1 was 
concentrated in the perinuclear region of 
the cell and showed a punctate distribution 
(III, Fig. 6). Double-staining with anti-
HEV antibodies in combination with 
organelle-specifi c markers was performed 
to explore the subcellular localization 
of pORF1 in more detail. HEV pORF1 
was found in close proximity to Golgi 
apparatus, but did not colocalize with 
the cis-Golgi matrix protein GM130 (III, 
Fig. 6). No colocalization was observed 
with ER markers PDI (protein disulfi de 
isomerase) and BAP. A signifi cant amount 
of pORF1 was found closely interspersed 
with staining of the ERGIC-53, a marker 
for the endoplasmic reticulum-Golgi 
intermediate compartment, but colocalized 
only to a small extent. Similar results were 
obtained with a shorter fragmet P110 (aa 
1-957). The N-terminal fragment MT496 
appeared as small globular masses (III, 
Fig. 6). The protein was distributed 
throughout the cytoplasm with slightly 
greater accumulation around the nucleus. 
All three C-terminal fragments X-HEL, 
POL and X-HEL-POL showed a similar 
localization pattern and were dispersed 
evenly throughout the cytoplasm. These 
results suggest that a specifi c localization 
signal, which directs the polyprotein to a 
restricted region in the cell, is located in 
the N-terminal part of the pORF1.
4. Membrane association and subcellular 
localization of SFV nonstructural 
polyprotein 
To study the role of the P1234 polyprotein 
and its cleavage intermediates in the 
membrane association and targeting of the 
SFV replication complex, we expressed 
the polyprotein precursor and its cleavage 
products (P123, P12, P23 and P34) as 
well as individual nonstructural proteins 
nsP1 to nsP4 in insect and mammalian 
cells (II, Fig.2). To prevent the processing 
of the polyprotein, we created constructs 
for expression of uncleaved nonstructural 
polyproteins by mutating the active-site 
cysteine 478 of nsP2 protease domain 
to alanine. The uncleaved polyproteins 
(designated P12CA34, P12CA3, P12CA 
and P2CA3) had properties previously 
identifi ed for the individually expressed 
nsPs, suggesting their proper folding 
in the precursor state. Flotation assays 
showed that uncleaved P12CA34, P12CA3, 
P12CA behaved similarly to nsP1 expressed 
alone, whereas P2CA3 and P34 did not 
fl oat, indicating that presence of nsP1 is 
required for the membrane association 
of the polyprotein (II, Fig. 3). The 
tight binding of the polyproteins to the 
membrane was due to the palmitoylation. 
The polyproteins P12CA34, P12CA3 and 
P2CA3 were also phosphorylated, like 
nsP3 (II, Fig. 3). The polyproteins, which 
contained nsP1 and nsP2 had enzymatic 
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activities specifi c for authentic nsPs. We 
have shown previously that nsP1 possess 
a unique methyltransferase activity, 
methylating GTP at position 7 of the 
guanine to produce m7GTP. The same 
protein acts also as a guanylyltransferase, 
which forms a covalent complex m7GMP-
nsP1 in the presence of AdoMet and [α-
32P]GTP (Ahola and Kääriäinen, 1995). 
Polyproteins P12CA34, P12CA3, P12CA, all of 
which contain nsP1, had methyltransferase 
as well as guanylyltransferase activity (II, 
Fig. 4). Polyproteins P12CA34, P12CA3, 
P12CA and P2CA3 had NTPase and RNA 
triphosphatase activities typical for nsP2. 
To study the role of nonstructural 
proteins in the intracellular targeting of 
the replication complex, the wild type 
polyproteins and their uncleaved forms 
were expressed in Hela cells. Expression 
of wild type P12 resulted in separation 
of nsP1 and nsP2. NsP1 was found at 
the plasma membrane and fi lopodia-like 
extensions, whereas nsP2 was transported 
to the nucleus (II, Fig. 5). In contrast, 
expression of uncleavable P12CA resulted 
in the accumulation of the protein at 
the plasma membrane and fi lopodia, 
indicating that the effect of nsP1 overrides 
the nuclear targeting of nsP2 domain in 
P12CA. Expression of P123 resulted in the 
dissociation of nsPs from each other. NsP1 
was localized at the plasma membrane, 
nsP2 was transported to the nucleus, and 
nsP3 was found in the cytoplasmic vesicle-
like structures. A different staining pattern 
was seen for P12CA3 (II, Fig. 5). The 
polyprotein was localized in large vesicle 
structures under the plasma membrane. 
Co-staining with anti-lamp-2 showed that 
some of these vesicles are of endosomal 
origin. No staining of fi lopodia similar to 
those in P12CA –expressing cells was seen. 
The localization of P12CA34 was similar to 
that shown for P12CA3. Thus, the presence 
of the nsP3 domain in the nonstructural 
polyprotein directed it to a new intracellular 
localization. These results suggest that 
nsP1 alone is responsible for membrane 
association of the polyprotein, whereas 
nsP3 together with nsP1 enables targeting 
of the replication complex to the surface 
of the endolysosomal vesicles.
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DISCUSSION
1. A unique cap formation pathway 
specifi c for alphavirus-like superfamily 
Viruses that replicate in the cytoplasm and 
are unable to use the nuclear transcription 
machinery of the host cell have developed 
their own transcription and capping 
systems. Although the structure of mRNA 
cap is identical, a variety of RNA viruses 
have diverse pathways for cap formation. 
It has been previously shown that both 
Sindbis virus and Semliki Forest virus nsP1 
have guanine-7-methyltransferase activity 
(Mi and Stollar, 1991; Laakkonen et al., 
1994). Next, it was demonstrated that this 
activity preceded a guanylyltransferase 
reaction, where nsP1 formed a covalent 
enzyme-guanylate complex (Ahola and 
Kääriäinen, 1995). These two reactions 
were part of a virus-specifi c capping of the 
mRNA. Since hepatitis E virus replicase 
proteins have a distant homology with those 
of alphaviruses, we wanted to test whether 
they share a similar capping mechanism. 
As a result of the present work, a unique 
mRNA capping pathway that is specifi c 
for hepatitis E virus and other members of 
the alphavirus-like superfamily has been 
characterized. We propose a following 
order of capping reactions catalyzed by 
viral enzymes, encoded by alpha-like 
viruses. 1) GTP and AdoMet bind to the 
enzyme at close proximity to each other. 
2) The methyl group from AdoMet is 
transferred to GTP resulting in formation 
of m7GTP and AdoHcy. 3) The covalent 
intermediate enzyme-m7GMP complex 
is formed via phosphoamid bond with an 
unidentifi ed amino acid. 4) The m7GMP is 
transferred to the 5′ end of nascent RNA, 
whose γ-phosphate has been removed 
by RNA-triphosphatase activity, to form 
the 5′ cap structure. This distinctive 
mRNA capping reaction is catalyzed by 
a group of distantly conserved AdoMet-
dependent guanylyltransferases and 
methyltransferases that were identifi ed 
in Semliki Forest virus (Ahola and 
Kääriäinen, 1995), tobacco mosaic virus 
(Merits at al., 1999), brome mosaic virus 
(Ahola and Ahlquist, 1999), bamboo 
mosaic virus (Li et al., 2001) and hepatitis 
E virus (this study).
Semliki Forest virus replicase protein 
nsP1 possess both activities required for cap 
formation: guanine-7-methyltransferase 
and guanylyltransferase (Ahola and 
Kääriäinen, 1995). Nsp1 is able to form 
a covalently bound enzyme-guanylate 
complex typical for guanylyltransferase. 
The complex consists of m7GMP, rather 
than GMP linked to nsP1. The synthesis 
of the alphavirus-specifi c complex 
differs from the previously characterized 
guanylyltransferases - GMP complexes 
in its absolute requirement for a methyl 
donor S-Adenosylmethionine. 
Methyltransferase activity and 
covalent complex formation exclusively 
with m7GMP have been demonstrated 
for replicase protein p126 of tobacco 
mosaic virus (Merits et al., 1999). TMV 
p126 is able to synthesize m7GTP using 
S-Adenosylmethionine as the methyl 
donor and catalyze the formation of 
covalent guanylate-p126 complex in 
the presence of AdoMet. Similar virus-
specifi c guanine-7-methyltransferase and 
covalent m7GMP binding activities were 
shown for brome mosaic virus protein 
1a (Ahola and Ahlquist, 1999). Analysis 
of reaction products by nuclear magnetic 
resonance spectroscopy demonstrated 
that methylation takes place only on the 
7-position of guanylate. The N-terminal 
442 amino acids of a 155kDa replicase of 
bamboo mosaic virus have been postulated 
to encompass an mRNA capping enzyme 
(Li et al., 2001). An AdoMet-dependent 
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guanylyltransferase activity and critical 
residues required for the capping reaction 
were characterized (Huang et al., 2004; 
Huang et al., 2005). 
NsP1-related proteins encoded 
by members of the alphavirus-like 
superfamily do not contain a conserved 
lysine residue, which forms covalent 
linkage with GMP in cellular enzymes. 
Instead, an absolutely conserved histidine 
(His38 for SFV, His81 for TMV, His80 for 
BMV, His68 for BaMV and His64 for HEV) 
(Fig. 8) is a good candidate for covalent 
binding with m7GMP, since the mutation 
of this residue completely abolished GT 
reaction without destroying MT activity 
(Ahola et al., 1997; Ahola and Ahlquist, 
1999; Merits et al., 1999; Huang et al., 
2004). Together with other characteristics 
such as their membrane-association nature 
and distinctive protein primary structures, 
this group of methyltransferases and 
guanylyltransferases represents a novel 
mRNA capping enzyme different from 
those of DNA viruses, metazoans and 
fungi. It is likely that all members of 
the alphavirus-like superfamily share 
a similar conserved mechanism of cap 
formation. Since it differs from cellular 
RNA capping, it offers a target for virus-
specifi c inhibitors of RNA replication, as 
discussed in IV.
2. Proteolytic processing of HEV 
nonstructural polyprotein 
The majority of positive-strand RNA 
viruses studied so far encode proteases 
that mediate viral polyprotein processing. 
However, an extensive search in the 
HEV polyprotein sequence for segments 
resembling all known types of viral and 
cellular proteases revealed no signifi cant 
similarity. The only region with very 
modest conservation was found among 
HEV polyprotein and putative cysteine 
papain-like proteases (PRO) of rubella 
virus and a plant benyvirus (Koonin at al, 
1992).
At present, the manner in which 
processing of the HEV ORF1 polyprotein 
into individual proteins occurs is not 
known. The proposed papain-like cysteine 
protease is presumed to play role, but host 
cell proteases may also be involved in the 
process. The papain-like cysteine protease 
is characteristic of alphaviruses and is also 
found in members of other plus-strand 
RNA virus families. Two residues, Cys481 
and His558, were shown to be members 
of the catalytic dyad in alphaviruses 
(Strauss et al., 1992). The mutagenesis of 
corresponding residue Cys478 in Semliki 
Forest virus nsP2 abolished the proteolysis 
of nonstructural polyprotein (Merits et 
al., 2001). In addition to alphaviruses, 
rubella virus and a beet necrotic yellow 
vein virus utilize the papain-like cysteine 
protease in the processing of their 
nonstructural polyproteins. In rubella 
virus the nonstructural ORF codes for a 
240 kDa polyprotein, which is cleaved by 
a virus-encoded protease to yield a 150 
kDa N-terminal product and a 90 kDa C-
terminal product. When cysteine residue 
Figure 8. Amino acid sequences encompass-
ing the conserved histidine residue of several 
capping enzymes within members of alphavi-
rus-like superfamily. HEV, SFV, BMV, TMV 
and BaMV are abbreviations for Hepatitis E 
virus, Semliki Forest virus, Brome mosaic vi-
rus, Tobacco mosaic virus and Bamboo mosaic 
virus, respectively.
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(Cys1151) proposed as the catalytic residue 
of this protease was mutated to a Gly, only 
the full-length polyprotein was produced 
(Marr et al., 1994). The BNYVV RNA1 
contains a single ORF that encodes for a 
220 kDa nonstructural polyprotein, which 
is autocatalytically processed into a150 
kDa N-terminal protein and a 60 kDa C-
terminal protein (Hehn et al., 1997).
Although the presence of papain-
like cysteine protease in hepatitis E virus 
has been predicted by computer-assisted 
analysis, the amino acid alignment 
between the putative HEV protease and 
other viral proteases was weak (Koonin et 
al., 1992). The catalytic residues predicted 
by computer alignment for HEV protease 
are Cys483 and His590. The cysteine residue 
is conserved among all HEV isolates, 
whereas His590 is not (Ropp et al., 2000). 
In Myanmar strain of HEV a tyrosine is 
found at position 590 and in Mexico strain 
this residue is a leucine. Thus, His590 is 
unlikely to be a catalytic residue. In the 
study by Ropp and colleagues, the full-
length HEV ORF1 was expressed in vitro 
using a coupled transcription/translation 
system and in vivo using a vaccinia virus-
aided transient expression system. Both in 
vitro and in vivo expression under standard 
conditions yielded only the full length 185 
kDa polyprotein. However, prolonged 
expression in vivo (24-36 hours) led to 
two potential processing products: an N-
terminal 78 kDa fragment containing the 
MT and PRO motifs and a C-terminal 
protein with the X, HEL and POL domains. 
The same result was observed in all four 
cell lines used in the experiment (HeLa, 
Vero, HepG2 and Chang Liver cells). The 
site-specifi c mutagenesis of the Cys483 
residue failed to abolish this cleavage, 
suggesting that either HEV polyprotein is 
not processed or it is cleaved at one site 
by a virus-encoded protease novel among 
alphavirus-like superfamily members. 
There is also a possibility that the cleavage 
observed after prolonged expression was 
mediated either by vaccinia virus vector or 
by a cellular enzyme. 
Another study demonstrated that 
no proteolytic processing of HEV 
nonstructural polyprotein (~ 186 kDa) was 
detected when only ORF1 was expressed 
in E. coli, in a cell free translation system 
or in HepG2 cells (Ansari et al., 2000). 
However, when the full-length genome 
of hepatitis E virus was expressed in the 
HepG2 cells, the presence of viral proteins 
pORF2, pORF3 and processed components 
of the ORF1 polyprotein was detected 
(Panda et al., 2000). In this experiment 
no ORF1 size protein was seen. Instead 
anti-polymerase antibody precipitated 
a protein with a molecular weight of 36 
kDa. Additionally, 35 and 38 kDa proteins 
were detected by anti-methyltransferase 
and anti-helicase antibodies, respectively. 
Our studies of proteolytic processing 
of HEV pORF1 suggest that the predicted 
papain-like cysteine protease either is not 
active or does not exist. In this respect HEV 
is similar to plant potexviruses, which 
express a single polyprotein responsible for 
methyltransferase, helicase and polymerase 
functions. The absence of protease 
within HEV nonstructural polyprotein 
is not characteristic for alphavirus-like 
superfamily, since other animal virus 
members (alphaviruses and rubella virus) 
use papain-like cysteine protease to 
catalyze cleavage of their polyproteins. 
However, our results obtained from the 
study of Semliki Forest virus polyprotein 
indicate that it does not have to be fully 
processed to mediate viral replication. In 
fact, the uncleaved polyprotein possessed 
enzymatic activities and other properties 
specifi c for the individual nonstructural 
proteins.
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3. Membrane association and intracellular 
distribution of HEV and SFV replicases
Compared to the alphaviruses our 
current knowledge of hepatitis E virus 
nonstructural proteins is limited and 
based mainly on the sequence homology 
analyses (Koonin and Dolja, 1993). It is 
known that all positive-strand RNA viruses 
replicate in the cytoplasm of the infected 
cells in association with various organelle-
specifi c membranes. The membranes 
play a structural and functional role by 
offering a suitable microenvironment for 
viral RNA synthesis and facilitate the 
recruitment of membrane-associated host 
factors required for the viral replication. In 
many cases, viral infection has a dramatic 
effect on the structure and function on 
the host cell membrane system. Different 
families of positive-strand RNA viruses 
appear to carry out RNA replication at 
different membrane sites or compartments 
of the cellular secretory and endocytic 
pathways. Alphaviruses and rubiviruses 
replicate in cytoplasmic structures defi ned 
as cytopathic vacuoles type I (CPV-I), 
which morphological features are quite 
well characterized by immunofl uorescence 
and electron microscopy studies (Grimley 
et al., 1968; Froshauer et al., 1988).  CPVs 
are modifi ed endosomes and lysosomes 
with a diameter of 200 to 1 000 nm. The 
cytosolic surface of CPVs consists of small 
invaginations with a diameter of about 50 
nm, which have been designated spherules 
(Froshauer et al., 1988). Previously 
it has been demonstrated that all four 
nonstructural proteins of Semliki Forest 
virus were associated with spherules 
together with nascent RNA, indicating 
that they are the sites of synthesis of plus-
strand RNA molecules (Kujala et al., 
2001). In the present study we have also 
shown that nsP1 alone is responsible for 
the membrane association of the replication 
complex, whereas the P123 intermediate 
is required for targeting to endosomes and 
lysosomes. 
Several plant viruses from the 
alphavirus-like superfamily replicate at 
the ER-derived membranes. For example, 
tobacco mosaic virus replication takes 
place in large structures, which originate 
from the ER and involve association 
with microfi laments, microtubules and 
virus-encoded, heavily phosphorylated 
movement protein (Mas et al., 1999). 
Brome mosaic virus RNA replication 
complexes colocalize with the ER markers, 
but not with the markers of Golgi or later 
compartments of the cellular secretory 
pathway (Restrepo-Hartwig and Ahlquist, 
1996). These macromolecular complexes 
are generated early during infection and 
consist of viral RNA, replicase proteins, 
host cell-derived membranes and host 
cell proteins. Studies of individual 
nonstructural proteins, the components 
of the RNA replicase, have revealed that 
the replication complexes are associated 
with the membranes and targeted to the 
respective organelle by the ns proteins 
rather than by RNA (Salonen et al., 
2005). Results obtained from our studies 
on membrane association of hepatitis E 
virus nonstructural polyprotein suggest 
that a localization signal, which directs the 
polyprotein to a specifi c membrane region 
in the cell, is located in its N-terminal 
part. By use of immunofl uorescence 
and confocal scanning microscopy, we 
observed that HEV replicase was localized 
in the perinuclear area of the cell and 
showed a reticular/punctate distribution. 
This staining pattern suggests that hepatitis 
E virus replicase polyprotein is most 
probably localized on the endoplasmic 
reticulum (ER) or ER-derived membranes. 
In this respect HEV is similar to another 
causative agent of viral hepatitis, hepatitis 
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C virus, a positive-strand RNA virus from 
the Flaviviridae family. The developmemt 
of effective replicon system enabled 
characterization of HCV replication 
complex in detail (Lohmann et al., 1999). All 
nonstructural proteins of hepatitis C virus 
were associated with the ER membranes, 
indicating that ER compartment is the 
site of membrane-associated HCV 
RNA replication (Mottola et al., 2002). 
Furthermore, electron microscopy 
revealed the loss of the ER organization 
and appearence of morphological 
alterations such as convoluted ER 
cisternae and paracrystalline structures. 
The development of effective cell culture 
system, which supports replication of 
hepatitis E virus, should allow us to 
achieve deeper level of understanding of 
events during viral replication.
4. Inhibitors of viral replication
Viral hepatitis is the most common 
infl ammatory liver disease with millions 
of new cases emerging worldwide every 
year. The disease is caused by one of fi ve 
primarily hepatotropic agents that have 
been designated the hepatitis viruses A, 
B, C, D and E (Chen, 2003). Although 
the acute disease caused by these fi ve 
viruses is clinically undistinguishable, the 
agents themselves are totally different, 
belonging to fi ve different virus families. 
Hepatitis viruses A and E are spread 
via the enteric route and usually cause 
a self-limiting hepatitis followed by 
complete recovery. Viruses B, C and D 
are transmitted by parenteral or mucosal 
exposure to infected blood. They are often 
associated with chronic liver disease that 
can lead to the development of cirrhosis 
and hepatocellular carcinoma. Currently, 
two therapeutic agents are used for the 
treatment of the hepatitis B infection: 
antiviral immunomodulator interferon-
α and lamivudine, an inhibitor of DNA 
polymerase and reverse transcriptase 
(Lok and McMahon, 2001). Alternatively, 
adefovir dipivoxil has been used for 
treatment of lamivudine-resistant chronic 
hepatitis B infection (Ocama et al., 2005). 
Effective immunization against hepatitis 
viruses A and B is now available. One 
vaccine candidate against hepatitis E 
infection has progressed to the stage of 
clinical trials and is currently evaluated in 
Nepal.
Despite numerous efforts, no vaccine 
is available against hepatitis C virus. 
Problems in the development of new anti-
HCV therapies include the persistence 
of the virus, genetic diversity during 
replication in the host and the development 
of drug-resistant mutants. Major research 
efforts have been aimed primarily at 
specifi c elements and enzymes, which 
mediate viral replication, with viral 
protease and polymerase being the most 
attractive targets. Several peptidomimetric 
protease inhibitors are at different stage of 
development. However, RNA-dependent 
RNA polymerase remains to be the most 
popular drug discovery target. Several 
nucleoside analogues that inhibit synthesis 
of viral RNA were identifi ed. They act 
as chain terminators upon incorporation 
into the nascent RNA molecule by viral 
polymerase. Furthermore, different class 
of agents that target the same viral enzyme 
were characterized. These non-nucleoside 
inhibitors block the polymerase, preventing 
a conformational transition required for 
initiation of RNA synthesis (De Francesco 
and Migliaccio, 2005).
However, in spite of encouraging 
results, the current therapy for hepatitis 
C virus still remains pegylated interferon 
in combination with ribavirin (Moradpour 
et al, 2002). Since its discovery in 
1972, ribavirin has been used against a 
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broad range of RNA and DNA viruses. 
Ribavirin is a synthetic purine nucleoside 
analogue with a structure closely related 
to guanosine. A number of possible 
mechanisms of action were proposed for 
ribavirin. For instance, it has been shown 
to inhibit host cell inosine monophosphate 
dehydrogenase, an enzyme that catalyzes 
a rate-limiting step in synthesis of GTP. 
This leads to a decreased pool of GTP 
levels in the cell, indirectly affecting 
the transcription of viral genomes and 
replication of RNA viruses (Tan et al., 2002). 
Ribavirin has been also shown to have an 
inhibitory effect on viral polymerases by 
competitively inhibiting the binding of the 
nucleotides. Incorporation of ribavirin into 
viral RNA drives the viruses beyond the 
critical mutation rate, thus forcing viruses 
into “error catastrophe” (Crotty et al., 
2001). It has been previously suggested 
that ribavirin has a negative effect on 
the capping of viral RNA transcripts 
(Goswami et al, 1979). Interestingly, the 
mutations in the Sindbis virus genome that 
confer resistance to ribavirin were mapped 
to the RNA guanylyltransferase encoding 
region (Scheidel and Stollar, 1991). 
Recent study demonstrated that ribavirin 
triphosphate can be used as a substrate by 
the vaccinia virus RNA capping enzyme 
and can form a covalent RMP-guanylate 
complex analogous to the classical GMP-
enzyme intermediate. Furthermore, it can 
be transferred to the diphosphate end of 
an RNA transcript to form the unusual 
RpppN structure (Bougie and Bisaillon, 
2004). This study showed that the RNA 
transcripts blocked with ribavirin could 
not be methylated and therefore, were not 
recognized by the translational machinery, 
leading to a decreased protein synthesis. 
Thus, ribavirin can directly interfere with 
viral RNA capping. Since cap structure 
is essential for mRNA translation and 
stability, viral enzymes involved in cap 
formation are attractive targets for the 
development of antiviral drugs (IV).
A number of cap analogs have been 
developed in recent years. In the study by 
Lampio and colleagues (1999) over 50 
guanosine analogs were tested for their 
effect on guanine-7-methyltransferase and 
guanylyltransferase activities of Semliki 
Forest capping enzyme nsP1. The most 
effective inhibitors of SFV capping enzyme 
contained a methyl group at position 7 of 
the guanine ring and one methyl or ethyl 
group at the position 2. Many cap analogs 
tested in this study appeared to be effi cient 
inhibitors of translation by competing with 
the 5′ cap of mRNAs for the binding to 
initiation factor eIF4E. Our current study 
described inhibitory effect of several cap 
analogs on the capping activity of hepatitis 
E virus enzyme. As expected, m7GTP and 
m7GDP were effi cient inhibitors of the 
HEV methyltransferase activity, which 
is in accordance with the properties 
of GTP and GDP as substrates for the 
methyltransferase (I). Interestingly, the 
double-substituted guanylate analogs were 
less effi cient inhibitors. It is likely, that 
the phosphorylation status of the analogs 
is more important than the substitutions 
of the guanylate moiety. The present 
work provides a novel approach for 
development of specifi c inhibitors against 
hepatitis E infection. As described above, 
the RNA capping pathway is conserved 
among all members of the alphavirus-like 
superfamily. Therefore, it may be possible 
to design compounds with broad-range 
antiviral properties.
Indeed, promising results with RNA 
capping inhibitors were obtained very 
recently in experiments with human 
respiratory syncytial virus (RSV), a 
negative-strand RNA virus (Liuzzi et 
al., 2005). In the case of RSV, viral 
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polymerase is responsible not only for the 
synthesis of both genomic and subgenomis 
mRNAs, but also for cotranscriptional 
capping and polyadenylation of mRNAs 
5′ and 3′ ends, respectively. In this study 
compounds that block synthesis of RSV 
mRNAs by preventing the guanylation of 
viral transcripts were characterized. It was 
shown that this class of RSV polymerase 
inhibitors increased the appearance of 
short uncapped RNA transcripts. Based 
on the results, it has been proposed that 
the inhibitors prevented cotranscriptional 
capping of viral mRNAs required for 
full elongation of transcripts. Thus, 
these inhibitors represent a novel class 
of nonnucleoside antiviral agents with a 
unique mechanism of action.
Another potential target for antiviral 
research is the membrane association 
of replication complexes, which is 
common to all positive-strand RNA 
viruses. The membrane association 
provides a structural framework for 
replication process and offers protection 
for the viral RNA molecules against host 
defence mechanisms (Salonen at al., 
2005). Different viruses utilize various 
intracellular membrane compartments, 
causing diverse modifi cations and 
rearrangements of the target membrane. 
The membranes can be derived from the 
ER, mitochondria, chloroplasts, or from 
the endo-lysosomal compartment (Salonen 
at al., 2005). However, in many cases the 
mechanisms of membrane binding and 
targeting of the replication complexes to 
specifi c intracellular organelles are poorly 
understood. Alphaviruses represent the 
fi rst example of structurally characterized 
membrane binding (Kääriäinen and Ahola, 
2002). In recent years, this fi eld of research 
has attracted an increased interest, which 
may lead to better understanding of the 
events taking place in the infected cells 
during viral replication. This knowledge, 
in turn, will provide new approaches for 
the development of antiviral drugs.
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